Associate Director
Kailera Therapeutics
Associate Director
Kailera Therapeutics
Clinical-stage obesity and metabolic drugs developer
At Kailera, we are bold, authentic and committed to our mission of developing therapies that give people the power to transform their lives and elevate their overall health. Rooted in an entrepreneurial spirit and a team-oriented culture, we are working together to advance Kailera’s mission to advance novel therapies for obesity and related conditions.
We are passionate about creating an inclusive workplace that promotes collaboration, integrity, and excellence. As we expand, we seek the most talented individuals with diverse backgrounds, cultures, perspectives, and experiences to join our team.
What You’ll Do:
The Associate Director, Clinical Scientist is a unique opportunity to play a key role in the research and development organization. This role allows for hands-on scientific responsibility of clinical trial execution and delivery. For this role, we are seeking a resourceful and matrixed individual who excels in operating at both the study team and leadership levels to lead in day-to-day execution, data review, and data analysis of the program in support of a Phase 3 pivotal study slated for NDA submission.
This opportunity requires a creative thinker who takes independent initiative to identify and address challenges, while working cross-functionally to drive the development and refinement of clinical and scientific processes and procedures in support of program deliverables.
This individual will assume increasing strategic and leadership responsibilities with broad external scientific communication from study start-up through reporting in support of a growing development portfolio.
Required location: Waltham, MA (hub-based, onsite 3-4 days per week)
Responsibilities:
In cooperation with the Clinical Science Asset Lead and key R&D stakeholders this individual will contribute to clinical strategy with the following expectations:
Required Qualifications:
Education:
For Full Time Roles: This range represents the company’s good-faith estimate of the salary at the time of posting. Actual pay may vary based on experience, skills, qualifications, location, and internal equity. We also offer comprehensive health coverage, flexible time off, paid holidays, and a year-end shutdown. Enjoy a monthly wellness stipend, generous 401(k) match, tuition reimbursement, commuter benefits, disability and life insurance, plus annual bonus opportunities and equity grants—because your well-being and future matter to us.
EQUAL EMPLOYMENT OPPORTUNITY INFORMATION:
Kailera Therapeutics, Inc. is an Equal Opportunity Employer that does not discriminate on the basis of actual or perceived race (including traits historically associated with race, such as hair texture and protective hairstyles), color, creed, religion (including religious dress and grooming practices), national origin, ancestry, citizenship status, age (40 and over), sex or gender (including pregnancy, childbirth, pregnancy-related conditions, and lactation), gender identity or expression (including transgender status), sexual orientation, marital status, military service and veteran status, physical or mental disability, genetic information, reproductive health decisions, domestic victim status, political affiliation, or any other characteristic protected by applicable federal, state, or local laws and ordinances.
E-Verify:
Kailera Therapeutics, Inc. uses E-Verify to confirm the identity and employment eligibility of all new hires.
#LI-Hybrid
Salary Range 159000 - 195000 USD
Clinical-stage obesity and metabolic drugs developer
Kailera Therapeutics focuses on obesity and related metabolic conditions by acquiring and developing clinical-stage drug candidates and moving them toward commercialization. Its lead asset, KAI-9531, is an injectable dual agonist of GLP-1 and GIP receptors for obesity and type 2 diabetes, and the pipeline includes an oral GLP-1 agonist (KAI-7535), an oral tablet form of KAI-9531, and an injectable tri-agonist targeting GLP-1, GIP, and glucagon receptors (KAI-4729). The company differentiates itself by sourcing assets outside of early research, pursuing a mix of injectable and oral therapies, and leveraging a high-profile leadership team and substantial funding to progress a broad portfolio under external licenses. Kailera’s goal is to advance multiple metabolic disease therapies from clinical development toward commercialization to improve outcomes for patients with obesity and related conditions.
Explore more opportunities at Kailera Therapeutics